Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup
Chai Discovery cofounders Josh Meier (left) and Jack Dent Cody Pickens for Forbes L ast June, when AI drug discovery…
Tag: Eli
Eli Lilly Grows Again in Genetic Medicines, Buying Startup With a New Way to Deliver DNA – MedCity News
Engineered viruses are a mainstay in genetic medicine due to their ability to ferry genetic cargo into cells. But limitations…
Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors – MedCity News
Antibody drug conjugates continue to be a robust area for research and dealmaking, and Eli Lilly’s latest move in this…
EXCLUSIVE: Healthcare Startup Andel Says Its Employer GLP-1 Model Bypasses PBMs, May Lower Costs For Eli Lilly’s Zepbound – Eli Lilly (NYSE:LLY)
A venture-backed healthcare startup wants to fix how employers pay for GLP-1s — without touching insurance. Andel launched its direct-to-employer…
Eli Lilly Expands Its In Vivo Ambitions, Acquiring Cell Therapy Startup Orna for up to $2.4B – MedCity News
The next frontier for cell therapy is shaping up to be in vivo treatments for autoimmune disease, and Eli Lilly…
From OpenAI’s offices to a deal with Eli Lilly — how Chai Discovery became one of the flashiest names in AI drug development | TechCrunch
Drug discovery, the art of identifying new molecules to develop pharmaceuticals, is a notoriously time-consuming and difficult process. Traditional techniques,…
AI healthcare enters a golden era of development! NVIDIA and Eli Lilly and Co invest in AI-driven drug discovery, while OpenAI acquires healthcare startup Torch.
AI healthcare concept stocks in the Hong Kong stock market collectively surged, $FANGZHOU JIANKE (06086.HK)$ with some rising over 36%,…
This former Eli Lilly exec just raised a $52 million seed round from family offices to build a new healthcare AI startup – Business Insider
Michelle Carnahan spent four years as the president of VC-backed healthcare startup Thirty Madison, and before that, had a two-decade-long…
Eli Lilly Challenges Custom Tirzepatide–But This Healthtech Startup Is Fighting Back
Eli Lilly (NYSE:LLY) just pre-announced a $1.57 billion pre-tax charge related to acquired in-process R&D, which is expected to weigh…